Scientific Programme - 6th Meeting of the EAU Section of Urological Imaging

Industry Session

Thu 16 November

View programme as: Grid view List view
Print: Print
Personal Planner

06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00

H1
Expo Hall

1. 06:00
2. 07:00
3. 08:00
4. 09:00
5. 10:00
6. 11:00
7. 12:00
8. 13:00
9. 14:00
10. 15:00
11. 16:00
12. 17:00
13. 18:00
14. 19:00
15. 20:00
16. 21:00
H1
1. Welcome by the ESUI
  
  Welcome by the ESUI
  
  08:30 - 08:35
  Welcome by the ESUI
  
  Thu 16 November
  08:30 - 08:35
  
  Location:
  
  H1
  
  08:30 - 08:35
  
  Welcome word
  
  G. Salomon, Hamburg (DE)
2. Improving effectiveness in diagnosis of prostate cancer - Part 1
  
  Improving effectiveness in diagnosis of prostate cancer - Part 1
  
  08:35 - 10:00
  Improving effectiveness in diagnosis of prostate cancer - Part 1
  
  Thu 16 November
  08:35 - 10:00
  
  Location:
  
  H1
  
  Moderators:
  
  J.J. Futterer, Nijmegen (NL)
  T. Loch, Flensburg (DE)
  A. Villers, Lille (FR)
  
  08:35 - 08:50
  
  What needs to be included in cost-effectiveness calculations in prostate cancer diagnosis?
  
  08:35 - 08:45
  
  M. de Rooij, Nijmegen (NL)
  
  08:45 - 08:50
  
  Discussion
  
  08:50 - 09:15
  
  Point and counterpoint in prostate cancer diagnosis 2.0: MRI before primary biopsy: Let’s break the bank with the costs?
  
  08:50 - 09:00
  
  Yes, this will break the bank
  
  N. Mottet, Saint-Étienne (FR)
  
  09:00 - 09:10
  
  No, this is cost-effective
  
  H.U. Ahmed, London (GB)
  
  09:10 - 09:15
  
  Discussion
  
  09:15 - 09:30
  
  What is more effective to select patients for prostate biopsy: Imaging vs. biomarkers
  
  09:15 - 09:25
  
  T. Nordström, Stockholm (SE)
  
  09:25 - 09:30
  
  Discussion
  
  09:30 - 09:45
  
  Quality issues of mp-MRI: The problem of re-do MRI and cost-effectiveness
  
  09:30 - 09:40
  
  J. Walz, Marseille (FR)
  
  09:40 - 09:45
  
  Discussion
  
  09:45 - 10:00
  
  What is an acceptable false negative rate in the detection of prostate cancer?
  
  09:45 - 09:55
  
  M.J. Roobol, Rotterdam (NL)
  
  09:55 - 10:00
  
  Discussion
3. Increasing the performance in the treatment of renal cell cancer
  
  Increasing the performance in the treatment of renal cell cancer
  
  10:30 - 12:00
  Increasing the performance in the treatment of renal cell cancer
  
  Thu 16 November
  10:30 - 12:00
  
  Location:
  
  H1
  
  Moderators:
  
  S. Siracusano, Trieste (IT)
  N. Wagener, Mannheim (DE)
  J. Walz, Marseille (FR)
  
  10:30 - 10:45
  
  3D-modeling of vascular anatomy for partial nephrectomy
  
  10:30 - 10:40
  
  V. Ficarra, Udine (IT)
  
  10:40 - 10:45
  
  Discussion
  
  10:45 - 11:00
  
  Active surveillance in renal cell cancer: When to switch to active treatment?
  
  10:45 - 10:55
  
  A. Volpe, Novara (IT)
  
  10:55 - 11:00
  
  Discussion
  
  11:00 - 11:15
  
  Assessment of response to targeted therapy in metastatic RCC by texture analysis
  
  11:00 - 11:10
  
  N. Wagener, Mannheim (DE)
  
  11:10 - 11:15
  
  Discussion
  
  11:15 - 11:30
  
  Expect the best, prepare for the worst: Prediction of adherent perirenal fat
  
  11:15 - 11:25
  
  V. Ficarra, ()
  
  11:25 - 11:30
  
  Discussion
  
  11:30 - 11:45
  
  Are we at the same level? Long term outcome of focal therapy of small renal masses vs. partial nephrectomy
  
  11:30 - 11:40
  
  S. Joniau, Leuven (BE)
  
  11:40 - 11:45
  
  Discussion
  
  11:45 - 12:00
  
  Summary and questions
4. Industry session - Lunch symposium: Axumin® (fluciclovine (<sup>18</sup>F)) - A Newly Approved Imaging Option for Recurrent Prostate Cancer - A Scientific Update
  
  Lunch symposium: Axumin® (fluciclovine (¹⁸F)) - A Newly Approved Imaging Option for Recurrent Prostate Cancer - A Scientific Update Industry session
  
  12:00 - 13:00
  Lunch symposium: Axumin® (fluciclovine (¹⁸F)) - A Newly Approved Imaging Option for Recurrent Prostate Cancer - A Scientific Update
  
  Industry session
  
  Thu 16 November
  12:00 - 13:00
  
  Location:
  
  H1
  
  Moderator:
  
  F. Willoch, Oslo (NO)
  
  12:00 - 12:05
  
  Welcome and introduction
  
  F. Willoch, Oslo (NO)
  
  12:05 - 12:20
  
  The FALCON Trial - A Phase 3 Study to assess the clinical utility of fluciclovine (¹⁸F) PET/CT imaging in patients with prostate cancer with biochemical recurrence
  
  F. Gleeson, Oxford (GB)
  
  12:20 - 12:35
  
  Clinical Experience of fluciclovine (¹⁸F) PET/CT imaging in men with suspected recurrent prostate cancer and PSA values <1ng/mL
  
  F. Willoch, Oslo (NO)
  
  12:35 - 12:50
  
  Initial experience with using (¹⁸F) fluciclovine in biochemically recurrent prostate cancer
  
  D. Wyndaele, Eindhoven (NL)
  
  12:50 - 13:00
  
  Summary and closing remarks
  
  F. Willoch, Oslo (NO)
5. Molecular imaging in Urology: Joint sessions of ESUI and EANM
  
  Molecular imaging in Urology: Joint sessions of ESUI and EANM
  
  13:00 - 14:10
  Molecular imaging in Urology: Joint sessions of ESUI and EANM
  
  Thu 16 November
  13:00 - 14:10
  
  Location:
  
  H1
  
  Moderators:
  
  S. Fanti, Bologna (IT)
  V. Scattoni, Milano (IT)
  
  13:00 - 13:15
  
  Cost-effectiveness and improvement of cancer control with PET/CT: Are we doing really better?
  
  13:00 - 13:10
  
  S. Fanti, Bologna (IT)
  
  13:10 - 13:15
  
  Discussion
  
  13:15 - 13:30
  
  Welcome back: Fluciclovine-PET in the management of prostate cancer
  
  13:15 - 13:25
  
  T. Bach-Gansmo, Oslo (NO)
  
  13:25 - 13:30
  
  Discussion
  
  13:30 - 13:45
  
  PSMA and the androgen receptor: A way to improve treatment monitoring of metastatic prostate cancer?
  
  13:30 - 13:40
  
  S. Fanti, Bologna (IT)
  
  13:40 - 13:45
  
  Discussion
  
  13:45 - 14:00
  
  New PET-tracers for renal cell cancer
  
  13:45 - 13:55
  
  R.C. Delgado-Bolton, Logroño (ES)
  
  13:55 - 14:00
  
  Discussion
  
  14:00 - 14:10
  
  Questions and Answers
6. Poster session and best abstract award
  
  Poster session and best abstract award
  
  14:10 - 14:55
  Poster session and best abstract award
  
  Thu 16 November
  14:10 - 14:55
  
  Location:
  
  H1
  
  Moderators:
  
  M. Mischi, Eindhoven (NL)
  G. Salomon, Hamburg (DE)
  
  EO1
  
  Feasibility Study for avoiding or postponing biopsy using improved imaging: Negative predictive value of micro-ultrasound for subjects with low PSAD
  
  By: Astobieta Odriozola A. ¹ , Sanchez A. ² , De La Cruz I. ² , Pereira J.G. ² , Gamarra M. ² , Urdaneta F. ² , Mora J. ² , Ibarluzea G. ²
  
  Institutes: ¹Urología Clínica Bilbao, Urología Clínica, Bilbao, Spain, ²Urología Clínica Bilbao, Clínica IMQ Zorrotzaurre, Bilbao, Spain
  
  14:14 - 14:16
  
  Discussion
  
  EO2
  
  Diagnostic accuracy of MRI-Transrectal Ultrasound Fusion prostate Biopsy in men with previous prostate biopsies: Preliminary results of the FUPROS16 project
  
  By: Gomez Gomez E.G.G. ¹ , Valero Rosa J. ² , Carrasco-Valiente J. ² , Lopez Ruiz D. ³ , Triviño F. ³ , Anglada-Curado F.J. ² , Blanca A. ⁴ , Campos Hernandez J.P. ² , Luque R.M. ⁵ , Requena Tapia M.J. ²
  
  Institutes: ¹Maimonides Institute of Biomedical Research of Cordoba/Reina Sofia University Hospital, Hormones and Cancer/urology, Cordoba, Spain, ²Maimonides Institute of Biomedical Research of Cordoba/Reina Sofia University Hospital, Dept. of Urology, Cordoba, Spain, ³Maimonides Institute of Biomedical Research of Cordoba/Reina Sofia University Hospital, Dept. of Radiology, Cordoba, Spain, ⁴Maimonides Institute of Biomedical Research of Cordoba, Dept. of Urology, Cordoba, Spain, ⁵Maimonides Institute of Biomedical Research of Cordoba/University of Cordoba, Dept. of Celular Biology, Cordoba, Spain
  
  14:20 - 14:22
  
  Discussion
  
  EO6
  
  Ultrasonographic study in patients affected by Peyronie’s disease with absence of palpable plaques or deformity of the penis
  
  By: Dell'Atti L. , Galosi A.B.
  
  Institutes: University Hospital "ospedali Riuniti", Dept. of Urology, Ancona, Italy
  
  14:26 - 14:28
  
  Discussion
  
  EO4
  
  MR spectroscopy provides distinction between malignant clear cell renal cancers and indolent subtypes
  
  By: Del Vecchio S. ¹ , Ellis R. ¹ , Urquhart A. ² , Galloway G. ² , Gobe G. ¹ , Mountford C. ² , Wood S. ³
  
  Institutes: ¹Translational Research Institute, Dept. of Kidney Disease Research, Woolloongabba, Australia, ²Translational Research Institute, Diagnostic Imaging Flagship, Brisbane, Australia, ³Princess Alexandra Hospital, Dept. of Urology, Brisbane, Australia
  
  14:32 - 14:34
  
  Discussion
  
  EO5
  
  11C-choline PET-guided salvage intensity modulated radiotherapy with simultaneous integrated boost for isolated pelvic and para-aortic prostate cancer nodal recurrences: Minimal adverse effects
  
  By: Jethwa K. ¹ , Davis B. ² , Hellekson C. ² , Evans J. ² , Whitaker T. ² , Wilhite T. ² , Park S. ² , Choo C. ² , Stish B. ² , Olivier K. ² , Lowe V. ³ , Johnson G. ³ , Mynderse L. ⁴ , Welch T. ³ , Quevedo F. ⁵ , Karnes R. ⁴ , Kwon E. ⁴
  
  Institutes: ¹Mayo Clinic, Dept. Of Radiation Oncology, Rochester, United States of America, ²Mayo Clinic, Dept. of Radiation Oncology, Rochester, United States of America, ³Mayo Clinic, Dept. of Radiology, Rochester, United States of America, ⁴Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁵Mayo Clinic, Dept. of Medical Oncology, Rochester, United States of America
  
  14:38 - 14:40
  
  Discussion
  
  EO3
  
  Ga-68 PSMA PETCT response to androgen deprivation therapy in patients with prostate cancer
  
  By: Murthy V. ¹ , Gupta P. ¹ , Agrawal A. ² , Maitre M. ¹ , Krishnatry R. ¹ , Rangarajan V. ²
  
  Institutes: ¹Tata Memorial Hospital, Dept. of Radiation Oncology, Mumbai, India, ²Tata Memorial Hospital, Dept. of Bioimaging, Mumbai, India
  
  14:44 - 14:46
  
  Discussion
  
  14:46 - 14:55
  
  Award best abstract
  
  G. Salomon, Hamburg (DE)
7. Improved management for urothelial cancer
  
  Improved management for urothelial cancer
  
  15:20 - 16:20
  Improved management for urothelial cancer
  
  Thu 16 November
  15:20 - 16:20
  
  Location:
  
  H1
  
  Moderators:
  
  S. Siracusano, Trieste (IT)
  N. Wagener, Mannheim (DE)
  
  15:20 - 15:35
  
  Standard work-up for micro-hematuria: What do the EAU guidelines tell?
  
  15:20 - 15:30
  
  M. Babjuk, Prague 5 (CZ)
  
  15:30 - 15:35
  
  Discussion
  
  15:35 - 15:50
  
  MRI in local staging of bladder cancer
  
  15:35 - 15:45
  
  C. Roy, Strasbourg (FR)
  
  15:45 - 15:50
  
  Discussion
  
  15:50 - 16:05
  
  Multiparametric cystoscopy
  
  15:50 - 16:00
  
  N. Wagener, Mannheim (DE)
  
  16:00 - 16:05
  
  Discussion
  
  16:05 - 16:20
  
  Immunotherapy: Imaging assessment of treatment response
  
  16:05 - 16:15
  
  N. Mehra, Nijmegen (NL)
  
  16:15 - 16:20
  
  Discussion
8. Improving effectiveness in diagnosis of prostate cancer - Part 2
  
  Improving effectiveness in diagnosis of prostate cancer - Part 2
  
  16:20 - 18:15
  Improving effectiveness in diagnosis of prostate cancer - Part 2
  
  Thu 16 November
  16:20 - 18:15
  
  Location:
  
  H1
  
  Moderators:
  
  A. Villers, Lille (FR)
  H. Wijkstra, Amsterdam (NL)
  
  16:20 - 16:50
  
  Point and counterpoint in prostate cancer diagnosis: How to manage PI-RADS 3 lesions
  
  16:20 - 16:30
  
  Can enhanced TRUS solve the problem?
  
  G. Salomon, Hamburg (DE)
  
  16:30 - 16:40
  
  Can predictive tools and biomarkers solve the problem?
  
  B.A. Hadaschik, Essen (DE)
  
  16:40 - 16:50
  
  Discussion
  
  16:50 - 17:05
  
  Up-date from the ESUR/ESUI MRI certification initiative
  
  16:50 - 17:00
  
  J. Walz, Marseille (FR)
  
  17:00 - 17:05
  
  Discussion
  
  17:05 - 17:20
  
  Transrectal or transperineal approach for fusion biopsy?
  
  17:05 - 17:15
  
  C. Kastner, Cambridge (GB)
  
  17:15 - 17:20
  
  Discussion
  
  17:20 - 17:35
  
  High resolution ultrasound and fusion biopsy
  
  17:20 - 17:30
  
  L. Budäus, Hamburg (DE)
  
  17:30 - 17:35
  
  Discussion
  
  17:35 - 18:15
  
  How to increase the performance of your prostate cancer diagnostic team
  
  17:35 - 17:45
  
  The radiologist’s point of view
  
  O. Rouviere, Lyon, Cedex (FR)
  
  17:45 - 17:55
  
  The urologist’s point of view
  
  C. Moore, London (GB)
  
  17:55 - 18:05
  
  The pathologist’s point of view
  
  R. Montironi, Ancona (IT)
  
  18:05 - 18:15
  
  Discussion
9. Summary and end of programme
  
  Summary and end of programme
  
  18:15 - 18:20
  Summary and end of programme
  
  Thu 16 November
  18:15 - 18:20
  
  Location:
  
  H1
  
  18:15 - 18:20
  
  Closing remarks by ESUI chair
  
  G. Salomon, Hamburg (DE)
Expo Hall
1. Coffee break & poster viewing
  
  Coffee break & poster viewing
  
  10:00 - 10:30
  Coffee break & poster viewing
  
  Thu 16 November
  10:00 - 10:30
  
  Location:
  
  Expo Hall
2. Coffee break & poster viewing
  
  Coffee break & poster viewing
  
  14:55 - 15:20
  Coffee break & poster viewing
  
  Thu 16 November
  14:55 - 15:20
  
  Location:
  
  Expo Hall

ESUI17

H1

Expo Hall

H1

Welcome by the ESUI

Improving effectiveness in diagnosis of prostate cancer - Part 1

Increasing the performance in the treatment of renal cell cancer

Lunch symposium: Axumin® (fluciclovine (¹⁸F)) - A Newly Approved Imaging Option for Recurrent Prostate Cancer - A Scientific Update

Molecular imaging in Urology: Joint sessions of ESUI and EANM

Poster session and best abstract award

Improved management for urothelial cancer

Improving effectiveness in diagnosis of prostate cancer - Part 2

Summary and end of programme

Expo Hall

Coffee break & poster viewing

Coffee break & poster viewing

Print Your Selection